United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - interferon alfa-2b - solution for injection - 10mega u/1ml

Israel - English - Ministry of Health

merck serono ltd - interferon beta 1a - solution for injection - interferon beta 1a 44 mcg/ml - interferon beta-1a - interferon beta-1a - rebif (interferone beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability. efficacy of rebif in chronic progressive multiple sclerosis has not been established.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - interferon alfa-2b 10 miu/ml;   - solution for injection - 10 miu/ml - active: interferon alfa-2b 10 miu/ml   excipient: dibasic sodium phosphate disodium edetate dihydrate metacresol monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

schering-plough a division of schering-plough animal health limited - interferon alfa-2b 5 miu/ml;   - solution for injection - 5 miu/ml - active: interferon alfa-2b 5 miu/ml   excipient: albumin dibasic sodium phosphate glycine methyl hydroxybenzoate monobasic sodium phosphate monohydrate propyl hydroxybenzoate water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - interferon alfa-2b 6 miu/ml;   - solution for injection - 6 miu/ml - active: interferon alfa-2b 6 miu/ml   excipient: dibasic sodium phosphate disodium edetate dihydrate metacresol monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - peginterferon alfa-2b 100ug; ribavirin 200mg;   - combination - 200mg+100µg(clearclick) - active: peginterferon alfa-2b 100ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose water for injection active: ribavirin 200mg   excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate tekprint blue sb-6018 titanium dioxide - pegatron combination therapy is indicated for the treatment of na?ve, relapse and non-responder patients with chronic hepatitis c (see clinical trials). patients must be 18 years of age or older and have compensated liver disease. pegatron combination therapy is also indicated for the treatment of patients with chronic hepatitis c who are co-infected with clinically stable hiv. interferon alfa monotherapy (including peg-intron) is indicated mainly in case of intolerance or contraindication to ribavirin. rebetol capsules must not be used alone because ribavirin is not effective as monotherapy in the treatment of hepatitis c. pegatron combination therapy is indicated for the treatment of chronic hepatitis c in children and adolescents with a bodyweight of nlt 27 kg with compensated liver disease and who have not received previous interferon treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - peginterferon alfa-2b 120ug; ribavirin 200mg;   - combination - 200mg+120µg(clearclick) - active: peginterferon alfa-2b 120ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose water for injection active: ribavirin 200mg   excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate tekprint blue sb-6018 titanium dioxide - pegatron combination therapy is indicated for the treatment of na?ve, relapse and non-responder patients with chronic hepatitis c (see clinical trials). patients must be 18 years of age or older and have compensated liver disease. pegatron combination therapy is also indicated for the treatment of patients with chronic hepatitis c who are co-infected with clinically stable hiv. interferon alfa monotherapy (including peg-intron) is indicated mainly in case of intolerance or contraindication to ribavirin. rebetol capsules must not be used alone because ribavirin is not effective as monotherapy in the treatment of hepatitis c. pegatron combination therapy is indicated for the treatment of chronic hepatitis c in children and adolescents with a bodyweight of nlt 27 kg with compensated liver disease and who have not received previous interferon treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - peginterferon alfa-2b 150ug; ribavirin 200mg;   - combination - 200mg+150µg(clearclick) - active: peginterferon alfa-2b 150ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose water for injection active: ribavirin 200mg   excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate tekprint blue sb-6018 titanium dioxide - pegatron combination therapy is indicated for the treatment of na?ve, relapse and non-responder patients with chronic hepatitis c (see clinical trials). patients must be 18 years of age or older and have compensated liver disease. pegatron combination therapy is also indicated for the treatment of patients with chronic hepatitis c who are co-infected with clinically stable hiv. interferon alfa monotherapy (including peg-intron) is indicated mainly in case of intolerance or contraindication to ribavirin. rebetol capsules must not be used alone because ribavirin is not effective as monotherapy in the treatment of hepatitis c. pegatron combination therapy is indicated for the treatment of chronic hepatitis c in children and adolescents with a bodyweight of nlt 27 kg with compensated liver disease and who have not received previous interferon treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - peginterferon alfa-2b 50ug; ribavirin 200mg;   - combination - 200mg+50µg (clearclick) - active: peginterferon alfa-2b 50ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose water for injection active: ribavirin 200mg   excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate tekprint blue sb-6018 titanium dioxide - pegatron combination therapy is indicated for the treatment of na?ve, relapse and non-responder patients with chronic hepatitis c (see clinical trials). patients must be 18 years of age or older and have compensated liver disease. pegatron combination therapy is also indicated for the treatment of patients with chronic hepatitis c who are co-infected with clinically stable hiv. interferon alfa monotherapy (including peg-intron) is indicated mainly in case of intolerance or contraindication to ribavirin. rebetol capsules must not be used alone because ribavirin is not effective as monotherapy in the treatment of hepatitis c. pegatron combination therapy is indicated for the treatment of chronic hepatitis c in children and adolescents with a bodyweight of nlt 27 kg with compensated liver disease and who have not received previous interferon treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - peginterferon alfa-2b 80ug; ribavirin 200mg;   - combination - 200mg+80µg(clearclick) - active: peginterferon alfa-2b 80ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose water for injection active: ribavirin 200mg   excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate tekprint blue sb-6018 titanium dioxide - pegatron combination therapy is indicated for the treatment of na?ve, relapse and non-responder patients with chronic hepatitis c (see clinical trials). patients must be 18 years of age or older and have compensated liver disease. pegatron combination therapy is also indicated for the treatment of patients with chronic hepatitis c who are co-infected with clinically stable hiv. interferon alfa monotherapy (including peg-intron) is indicated mainly in case of intolerance or contraindication to ribavirin. rebetol capsules must not be used alone because ribavirin is not effective as monotherapy in the treatment of hepatitis c. pegatron combination therapy is indicated for the treatment of chronic hepatitis c in children and adolescents with a bodyweight of nlt 27 kg with compensated liver disease and who have not received previous interferon treatment.